All News

Video: What Kind of Diet Should You be on? with Dr. Robert Chao ( @doctorRBC) https://t.co/jqkA8vrgww #EULAR2021 https://t.co/5mPuZWmw20

Links:

Dr. John Cush RheumNow ( View Tweet)
We need to revisit #SLEDAI #lupus arthritis. Drs Mahmoud & Vital reported only 48% without swelling had MSK-US synovitis; 90% with swelling. They proposed new TERM: Inflammatory joint pain with =>2 SJC. Need to get this right as it impacts SRI-4 #EULAR2021 #POS0746 @RheumNow https://t.co/JPqOMLQ2ES
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Apremilast in Behcet’s - RELIEF European subgroup analysis ⬇️oral ulcer count, ulcer pain, disease activity ⬆️QoL ⭐️results consistent with general population Abs#POS0254 #EULAR2021 @RheumNow https://t.co/NVGt4TjkYY
Robert B Chao, MD doctorRBC ( View Tweet)
Yesterday at #EULAR2021: Spacing trial: success in taper anti-TNF for stable SpA. POS0229 C-OPTIMSE study: Certolizumab w/d for SpA remission (continue full dose vs. 1/2 dose vs. placebo). Placebo group had ⬆️ activity scores, 77% flared. Ok to taper, but won't stop Rx @Rheumnow

Eric Dein ejdein1 ( View Tweet)

#EULAR2021 - Key points from Dr. Mease's oral abstract: ⭐️AxSpA pts were younger & more likely to be male & have a hx of uveitis & IBD ⭐️AxSpA pts had less exposure to prior therapies relative to axPsA pts ⭐️AxSpA assoc w/ > spinal pain regardless of b/tsDMARD status @Rheumnow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Dr Palomäki on influence of MUC5B promotor variant on ILD risk in RA and non-RA. Lifetime risk ILD 14.5% for RA+MUC5B+, 5.2% for RA+MUC5B-, 3.9% RA-MUC5B+ 1.3% RA-MUC5B- @RheumNow #EULAR2021 Abstr#OP0007 https://t.co/BnexQE1Pw9
Richard Conway RichardPAConway ( View Tweet)
Dr. G Robinson Abstr#OP0013 on sex link b/t autoimmune & CV risk 👉Hormones drive funx change in Treg transciptome 👉anti-inflamm Tregs⬆️in males 👉Tregs are more suppressive in males 👉Treg transciptome profile altered b/t males & females in autoimmunity #EULAR2021 @rheumnow https://t.co/p4Awfu2hiK
k dao KDAO2011 ( View Tweet)
ILD in RA is a killer! @eular_org abst OP0099 Admin day from France claims database. ILD was clinically dx in 2.5% & had 3X mortality. Low prevalence compared to some studies of 6% so maybe worst cases but Impt cause of excess death in RA @RheumNow @eular_org @jeffsparks https://t.co/mPfpPSHxsd
Janet Pope Janetbirdope ( View Tweet)
Vaccine2.jpg (keep)

Methotrexate Impairs COVID Vax Response

d MedPage Today

One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.

Read Article
Virtual DDW meeting this wk reports claims data comparing IBD to IBD with RA - IBD alone vs IBD w/ RA dx w/ more depression (21% vs 84%), anxiety (20% vs 47%). IBD w/ RA had more depression (OR 7.2); anxiety (OR, 1.25;) or both (OR, 2.3) https://t.co/B78xcJw584

Links:

Dr. John Cush RheumNow ( View Tweet)

News: Factors Associated with COVID-19 Deaths in Rheumatic Patients https://t.co/FzsINtpZEz https://t.co/QzuLZRKaZy

Links:

Dr. John Cush RheumNow ( View Tweet)
Checkpoint Inhibitor Safety in Melanoma Patients with AID A study from the DMT shows that the use of checkpoint inhibitors for advanced melanoma in AID patients didn't increase the risk of irAEs, except for those with preexisting IBD. https://t.co/VFzBOlc0wc https://t.co/0zfr8YFmZr

Links:

Dr. John Cush RheumNow ( View Tweet)
colonperf.png

Tocilizumab Risk of Diverticulitis and GI Perforation

d Jack Cush, MD

A French registry analysis compared the risk of diverticulitis and gastrointestinal perforation (GIP) in rheumatoid arthritis (RA) patients treated with biologics and found a greater risk of both in patients receiving tocilizumab (TCZ) compared with those on rituximab (RTX) or abatacept (ABA

Read Article
Rituximab Tops Mycophenolate Mofetil for Pemphigus Vulgaris. One year study of 135 moderate-to-severe pemphigus patients saw complete remission in 40% of RTX vs 10% of MMF patients. https://t.co/yAauFRjHCe

Links:

Dr. John Cush RheumNow ( View Tweet)

"Arthritis Mutilans" - worse outcome to chronic inflammatory arthritis is due to 5 disorders: 1) RA 2) Psoriatic arthritis 3) Tophaceous gout 4) polyarticular JIA 5) Multicentric reticulohistiocytosis (Ive never seen this!!) https://t.co/XYmBEW1F0R https://t.co/tGWNG9Aklw

Links:

Dr. John Cush RheumNow ( View Tweet)

"Arthritis Mutilans" - worse outcome to chronic inflammatory arthritis is due to 5 disorders: 1) RA 2) Psoriatic arthritis 3) Tophaceous gout 4) polyarticular JIA 5) Multicentric reticulohistiocytosis (Ive never seen this!!) https://t.co/XYmBEW1F0R https://t.co/tGWNG9Aklw

Links:

Dr. John Cush RheumNow ( View Tweet)

NSAIDs.pills_.caps_.jpg

NSAID Safety with COVID-19 Infection

d Jack Cush, MD

NSAIDs do not affect COVID outcomes; here we are nearly 16 months into the pandemic, and this is the common sense conclusion of a recent trial published in Lancet Rheumatology.

Read Article
News Feature: Autoimmune Thyroid Disease in Women JAMA has posted an insights article reviewing autoimmune thyroid disease in women. Thyroid autoimmunity has a higher prevalence in women and with increasing age. https://t.co/P55lMMagyO https://t.co/yMWJClvVJO

Links:

Dr. John Cush RheumNow ( View Tweet)
27 cases of #immune-mediated diseases post #COVIDVaccination ▶️21 had autoimmune/rheumatic background ▶️17 flares, 10 new onset ▶️Average 4 days post #covidvaccine ▶️>80% had resolution, mostly with corticosteroid 👉🏽https://t.co/zHlFziswU7 via @Vaccines_MDPI @MDPIOpenAccess https://t.co/5ifoBmb9Ux

Links:

Dr Ai Lyn Tan DrAiLynTan ( View Tweet)

CARD8 SNP rs11672725 (OR 3) may be a Genetic Variant for AdultStill’s Disease. AOSD has unregulated NLR3 inflammasome activity. Study of 66 AOSD & 128 controls, showed AOSD to have low CARD8, higher caspase-1, IL-1β and IL-18; more systemic Sxs https://t.co/rpypR4cLfM

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.